Today, the reporter learned from the Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee that the overall scale of Beijing's pharmaceutical and health industry will reach 1.06 trillion yuan in 2024, a year-on-year increase of 8.7%, becoming the first city in China to break through the trillion yuan mark in the pharmaceutical and health industry. The pharmaceutical and health industry is one of the "dual engines" driving innovation and development in Beijing. Since 2018, Beijing has continued to implement three rounds of the "Action Plan" to accelerate collaborative innovation in medicine and health. In January and February of this year, seven innovative pharmaceutical and medical products were approved for market in Beijing, ranking first in the country in terms of quantity and achieving a "good start". In 2024, 11 AI Class III medical devices will be approved for market in Beijing, ranking first in the country in terms of quantity; Nine innovative medical devices have been approved for listing, ranking second in the country; Nine innovative drugs have been included in breakthrough treatment varieties, ranking third in the country. In 2024, Beijing launched 32 measures to support the development of innovative medicine. In the past year of implementation, Beijing has implemented the national innovation pilot program of "reducing the approval time limit for drug clinical trials from 60 days to 30 days, and reducing the review time limit for drug supplementary applications from 200 days to 60 days", released two batches of 16 clinical trial pilot institutions, and promoted the inclusion of 8 innovative drug clinical trial projects in the pilot program. In 2024, 8 well-known foreign-funded pharmaceutical and equipment enterprises will establish new research and development or innovation entities in Beijing. Among them, Sanofi will invest about 1 billion euros to build a new insulin production base in the Economic Development Zone, which is the company's largest single investment in China; GE Healthcare Beijing Imaging Equipment Manufacturing Base has been awarded the title of "Lighthouse Factory", becoming the first "Lighthouse Factory" in China's medical equipment industry. In addition, Beijing is focusing on increasing the introduction of foreign talents, clinical achievement transformation and other talents, promoting the implementation of clinical physician scientist training, launching a CEO talent training program for service scientists in the pharmaceutical field, and holding 12 consecutive pharmaceutical and health advanced research courses. In 2024, Beijing will establish a pharmaceutical and health industry investment fund, focusing on the "two ends" of early research and development and industrialization, and completing 44 investment decisions, with a total investment amount and driving social capital investment of nearly 9 billion yuan. Next, Beijing will deepen the implementation and effectiveness of the third round of the "Action Plan", accelerate the output of innovative pharmaceutical and medical achievements, and focus on industrialization and large-scale production. (New Society)